CTLA4 and neoplasm: KN046, a bsAb targeting PD-L1 and CTLA-4, was shown in preclinical mouse model trials by Jiang et al. [66] to cause significant increases in the percentage of CD3+ CD4+ and CD3+ CD8+ T cells in the tumor and spleen, indicating a robust in vivo immune response.